Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Payables (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Payables data on record, last reported at $4.2 million in Q4 2025.

  • For Q4 2025, Payables fell 0.53% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, down 0.53%, while the annual FY2025 figure was $4.2 million, 0.53% down from the prior year.
  • Payables reached $4.2 million in Q4 2025 per OCUL's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Payables topped out at $12.4 million in Q1 2021 and bottomed at $3.4 million in Q1 2022.
  • Average Payables over 5 years is $5.1 million, with a median of $4.5 million recorded in 2021.
  • Peak YoY movement for Payables: soared 153.25% in 2021, then plummeted 72.51% in 2022.
  • A 5-year view of Payables shows it stood at $4.6 million in 2021, then rose by 11.56% to $5.1 million in 2022, then decreased by 14.33% to $4.4 million in 2023, then decreased by 4.85% to $4.2 million in 2024, then dropped by 0.53% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $4.2 million in Q4 2025, $6.3 million in Q3 2025, and $5.9 million in Q2 2025.